La	O
temozolomida	O
(	O
TMZ	O
)	O
es	O
un	O
agente	O
alquilante	O
autorizado	O
para	O
el	O
tratamiento	O
del	O
glioma	O
de	O
alto	O
grado	O
(	O
HGG	O
)	O
.	O

No	O
existe	O
una	O
comparación	O
prospectiva	O
con	O
la	O
quimioterapia	O
basada	O
en	O
nitrosourea	O
.	O

Informamos	O
,	O
hasta	O
donde	O
sabemos	O
,	O
el	O
primer	O
ensayo	O
aleatorizado	O
de	O
procarbazina	O
,	O
lomustina	O
y	O
vincristina	O
(	O
PCV	O
)	O
versus	O
TMZ	O
en	O
pacientes	O
sin	O
tratamiento	O
previo	O
con	O
quimioterapia	O
con	O
HGG	O
recurrente	O
.	O

Cuatrocientos	O
cuarenta	O
y	O
siete	O
pacientes	O
fueron	O
asignados	O
aleatoriamente	O
a	O
PCV	O
(	O
224	O
pacientes	O
)	O
o	O
TMZ	O
(	O
asignación	O
subaleatoria	O
:	O
TMZ-5	O
[	O
200	O
mg/m	O
(	O
2	O
)	O
durante	O
5	O
días	O
,	O
112	O
pacientes	O
]	O
o	O
TMZ-21	O
[	O
100	O
mg/m	O
(	O
2	O
)	O
durante	O
21	O
días	O
,	O
111	O
pacientes	O
]	O
)	O
hasta	O
9	O
meses	O
o	O
hasta	O
la	O
progresión	O
.	O

Los	O
resultados	O
primarios	O
fueron	O
la	O
supervivencia	O
(	O
PCV	O
frente	O
a	O
TMZ	O
)	O
y	O
la	O
supervivencia	O
libre	O
de	O
progresión	O
a	O
las	O
12	O
semanas	O
(	O
PFS	O
;	O
TMZ-5	O
frente	O
a	O
TMZ-21	O
)	O
.	O

Este	O
estudio	O
está	O
registrado	O
como	O
ISRCTN83176944	O
.	O

Los	O
porcentajes	O
de	O
pacientes	O
que	O
completaron	O
9	O
meses	O
de	O
tratamiento	O
en	O
los	O
brazos	O
PCV	O
,	O
TMZ-5	O
y	O
TMZ-21	O
fueron	O
17	O
%	O
,	O
26	O
%	O
y	O
13	O
%	O
,	O
respectivamente	O
.	O

La	B-Premise-Support-4
toxicidad	I-Premise-Support-4
principal	I-Premise-Support-4
fue	I-Premise-Support-4
similar	I-Premise-Support-4
en	I-Premise-Support-4
los	I-Premise-Support-4
tres	I-Premise-Support-4
grupos	I-Premise-Support-4
.	I-Premise-Support-4

Con	B-Premise-Support-3
una	I-Premise-Support-3
mediana	I-Premise-Support-3
de	I-Premise-Support-3
tiempo	I-Premise-Support-3
de	I-Premise-Support-3
seguimiento	I-Premise-Support-3
de	I-Premise-Support-3
12	I-Premise-Support-3
meses	I-Premise-Support-3
y	I-Premise-Support-3
382	I-Premise-Support-3
muertes	I-Premise-Support-3
,	I-Premise-Support-3
no	I-Premise-Support-3
hubo	I-Premise-Support-3
un	I-Premise-Support-3
claro	I-Premise-Support-3
beneficio	I-Premise-Support-3
de	I-Premise-Support-3
supervivencia	I-Premise-Support-3
al	I-Premise-Support-3
comparar	I-Premise-Support-3
PCV	I-Premise-Support-3
con	I-Premise-Support-3
TMZ	I-Premise-Support-3
(	I-Premise-Support-3
cociente	I-Premise-Support-3
de	I-Premise-Support-3
riesgos	I-Premise-Support-3
instantáneos	I-Premise-Support-3
[	I-Premise-Support-3
HR	I-Premise-Support-3
]	I-Premise-Support-3
,	I-Premise-Support-3
0,91	I-Premise-Support-3
;	I-Premise-Support-3
IC	I-Premise-Support-3
del	I-Premise-Support-3
95	I-Premise-Support-3
%	I-Premise-Support-3
,	I-Premise-Support-3
0,74	I-Premise-Support-3
a	I-Premise-Support-3
1,11	I-Premise-Support-3
;	I-Premise-Support-3
P	I-Premise-Support-3
=	I-Premise-Support-3
0,350	I-Premise-Support-3
)	I-Premise-Support-3
.	I-Premise-Support-3

Para	B-Premise-Support-2
TMZ-5	I-Premise-Support-2
versus	I-Premise-Support-2
TMZ-21	I-Premise-Support-2
,	I-Premise-Support-2
las	I-Premise-Support-2
tasas	I-Premise-Support-2
de	I-Premise-Support-2
SLP	I-Premise-Support-2
a	I-Premise-Support-2
las	I-Premise-Support-2
12	I-Premise-Support-2
semanas	I-Premise-Support-2
fueron	I-Premise-Support-2
similares	I-Premise-Support-2
(	I-Premise-Support-2
63,6	I-Premise-Support-2
%	I-Premise-Support-2
y	I-Premise-Support-2
65,7	I-Premise-Support-2
%	I-Premise-Support-2
,	I-Premise-Support-2
respectivamente	I-Premise-Support-2
;	I-Premise-Support-2
P	I-Premise-Support-2
=	I-Premise-Support-2
0,745	I-Premise-Support-2
)	I-Premise-Support-2
,	I-Premise-Support-2
pero	B-Premise-Partial_Attack--1
TMZ-5	I-Premise-Partial_Attack--1
mejoró	I-Premise-Partial_Attack--1
la	I-Premise-Partial_Attack--1
SLP	I-Premise-Partial_Attack--1
general	I-Premise-Partial_Attack--1
(	I-Premise-Partial_Attack--1
HR	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
1,38	I-Premise-Partial_Attack--1
;	I-Premise-Partial_Attack--1
IC	I-Premise-Partial_Attack--1
del	I-Premise-Partial_Attack--1
95	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
1,05	I-Premise-Partial_Attack--1
a	I-Premise-Partial_Attack--1
1,82	I-Premise-Partial_Attack--1
;	I-Premise-Partial_Attack--1
P	I-Premise-Partial_Attack--1
=	I-Premise-Partial_Attack--1
0,023	I-Premise-Partial_Attack--1
)	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
supervivencia	I-Premise-Partial_Attack--1
(	I-Premise-Partial_Attack--1
HR	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
1,32	I-Premise-Partial_Attack--1
;	I-Premise-Partial_Attack--1
IC	I-Premise-Partial_Attack--1
del	I-Premise-Partial_Attack--1
95	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
0,99	I-Premise-Partial_Attack--1
a	I-Premise-Partial_Attack--1
1,75	I-Premise-Partial_Attack--1
;	I-Premise-Partial_Attack--1
P	I-Premise-Partial_Attack--1
=	I-Premise-Partial_Attack--1
0,056	I-Premise-Partial_Attack--1
)	I-Premise-Partial_Attack--1
y	I-Premise-Partial_Attack--1
calidad	I-Premise-Partial_Attack--1
de	I-Premise-Partial_Attack--1
vida	I-Premise-Partial_Attack--1
global	I-Premise-Partial_Attack--1
(	I-Premise-Partial_Attack--1
49	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
frente	I-Premise-Partial_Attack--1
a	I-Premise-Partial_Attack--1
19	I-Premise-Partial_Attack--1
%	I-Premise-Partial_Attack--1
mejoró	I-Premise-Partial_Attack--1
>	I-Premise-Partial_Attack--1
10	I-Premise-Partial_Attack--1
puntos	I-Premise-Partial_Attack--1
a	I-Premise-Partial_Attack--1
los	I-Premise-Partial_Attack--1
6	I-Premise-Partial_Attack--1
meses	I-Premise-Partial_Attack--1
,	I-Premise-Partial_Attack--1
respectivamente	I-Premise-Partial_Attack--1
;	I-Premise-Partial_Attack--1
P	I-Premise-Partial_Attack--1
=	I-Premise-Partial_Attack--1
.005	I-Premise-Partial_Attack--1
)	I-Premise-Partial_Attack--1
.	I-Premise-Partial_Attack--1

Aunque	B-Claim-Support-1
TMZ	I-Claim-Support-1
(	I-Claim-Support-1
ambos	I-Claim-Support-1
brazos	I-Claim-Support-1
combinados	I-Claim-Support-1
)	I-Claim-Support-1
no	I-Claim-Support-1
mostró	I-Claim-Support-1
un	I-Claim-Support-1
claro	I-Claim-Support-1
beneficio	I-Claim-Support-1
en	I-Claim-Support-1
comparación	I-Claim-Support-1
con	I-Claim-Support-1
PCV	I-Claim-Support-1
,	I-Claim-Support-1
la	I-Claim-Support-1
comparación	I-Claim-Support-1
de	I-Claim-Support-1
los	I-Claim-Support-1
programas	I-Claim-Support-1
de	I-Claim-Support-1
TMZ	I-Claim-Support-1
demostró	I-Claim-Support-1
que	I-Claim-Support-1
el	I-Claim-Support-1
programa	I-Claim-Support-1
de	I-Claim-Support-1
21	I-Claim-Support-1
días	I-Claim-Support-1
fue	I-Claim-Support-1
inferior	I-Claim-Support-1
al	I-Claim-Support-1
programa	I-Claim-Support-1
de	I-Claim-Support-1
5	I-Claim-Support-1
días	I-Claim-Support-1
en	I-Claim-Support-1
este	I-Claim-Support-1
contexto	I-Claim-Support-1
.	I-Claim-Support-1

Esto	B-Claim
desafía	I-Claim
la	I-Claim
comprensión	I-Claim
actual	I-Claim
de	I-Claim
aumentar	I-Claim
la	I-Claim
intensidad	I-Claim
de	I-Claim
la	I-Claim
dosis	I-Claim
de	I-Claim
TMZ	I-Claim
mediante	I-Claim
una	I-Claim
programación	I-Claim
prolongada	I-Claim
.	I-Claim

